These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1063 related items for PubMed ID: 32852721

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, Cuenot F, Penso L, Herlemont P, Sbidian E, Weill A, Dray-Spira R, Zureik M.
    Hypertension; 2021 Mar 03; 77(3):833-842. PubMed ID: 33423528
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP.
    PLoS One; 2021 Mar 03; 16(4):e0248080. PubMed ID: 33891615
    [Abstract] [Full Text] [Related]

  • 4. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
    Haroon S, Subramanian A, Cooper J, Anand A, Gokhale K, Byne N, Dhalla S, Acosta-Mena D, Taverner T, Okoth K, Wang J, Chandan JS, Sainsbury C, Zemedikun DT, Thomas GN, Parekh D, Marshall T, Sapey E, Adderley NJ, Nirantharakumar K.
    BMC Infect Dis; 2021 Mar 15; 21(1):262. PubMed ID: 33722197
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT, Zhang H, Chen T, Malhotra N.
    Am J Nephrol; 2021 Mar 15; 52(3):250-260. PubMed ID: 33827074
    [Abstract] [Full Text] [Related]

  • 6. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration.
    Vascul Pharmacol; 2020 Dec 15; 135():106805. PubMed ID: 32992048
    [Abstract] [Full Text] [Related]

  • 7. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study.
    de Abajo FJ, Rodríguez-Miguel A, Rodríguez-Martín S, Lerma V, García-Lledó A, MED-ACE2-COVID19 Study Group.
    BMC Med; 2021 May 12; 19(1):118. PubMed ID: 33980231
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Association of renin-angiotensin-aldosterone system inhibition with Covid-19 hospitalization and all-cause mortality in the UK biobank.
    Safizadeh F, Nguyen TNM, Brenner H, Schöttker B.
    Br J Clin Pharmacol; 2022 Jun 12; 88(6):2830-2842. PubMed ID: 34935181
    [Abstract] [Full Text] [Related]

  • 10. Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia.
    Lee HY, Ahn J, Park J, Kang CK, Won SH, Kim DW, Park JH, Chung KH, Joh JS, Bang JH, Kang CH, Oh MD, Pyun WB, Korean Society of Hypertension, National Committee for Clinical Management of Emerging Infectious Diseases.
    Korean J Intern Med; 2021 May 12; 36(3):617-628. PubMed ID: 33858123
    [Abstract] [Full Text] [Related]

  • 11. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A, Mancone M, De Ferrari GM, Forleo G, Secco GG, Ruocco GM, D'Ascenzo F, Monticone S, Paggi A, Vicenzi M, Palazzo AG, Landolina M, Taravelli E, Tavazzi G, Blasi F, Infusino F, Fedele F, De Rosa FG, Emmett M, Schussler JM, Tecson KM, McCullough PA.
    J Am Heart Assoc; 2020 Nov 17; 9(22):e017364. PubMed ID: 33023356
    [Abstract] [Full Text] [Related]

  • 12. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S, Xiao X, Qin Q.
    J Med Virol; 2021 Mar 17; 93(3):1370-1377. PubMed ID: 33095513
    [Abstract] [Full Text] [Related]

  • 13. Risk of Covid-19-Related Hospitalization and More Severe Outcomes in Medicare Beneficiaries Treated with Renin-Angiotensin-Aldosterone System Inhibitors for Hypertension.
    Graham DJ, Izurieta HS, Muthuri SG, Zhang D, Sandhu AT, Lu Y, Zhao Y, Feng Y, Eworuke E, Lyu H, Gandotra C, Smith ER, Avagyan A, Wernecke M, Kelman JA, Forshee RA, MaCurdy TE.
    J Gen Intern Med; 2021 Dec 17; 36(12):3802-3809. PubMed ID: 34599472
    [Abstract] [Full Text] [Related]

  • 14. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, Vassiliou VS.
    JAMA Netw Open; 2021 Mar 01; 4(3):e213594. PubMed ID: 33787911
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ, Noordzij M, Abramowicz D, de Arriba G, Basile C, van Buren M, Covic A, Crespo M, Duivenvoorden R, Massy ZA, Ortiz A, Sanchez JE, Petridou E, Stevens K, White C, Vart P, Gansevoort RT, ERACODA Collaborators.
    Clin J Am Soc Nephrol; 2021 Jul 01; 16(7):1061-1072. PubMed ID: 34088718
    [Abstract] [Full Text] [Related]

  • 17. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, Schou M, Phelps M, Gislason GH, Gerds TA, Torp-Pedersen C, Køber L.
    JAMA; 2020 Jul 14; 324(2):168-177. PubMed ID: 32558877
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
    An J, Wei R, Zhou H, Luong TQ, Gould MK, Mefford MT, Harrison TN, Creekmur B, Lee MS, Sim JJ, Brettler JW, Martin JP, Ong-Su AL, Reynolds K.
    J Am Heart Assoc; 2021 Feb 02; 10(3):e019669. PubMed ID: 33307964
    [Abstract] [Full Text] [Related]

  • 19. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes.
    Bezabih YM, Bezabih A, Alamneh E, Peterson GM, Bezabhe W.
    BMC Infect Dis; 2021 Jun 05; 21(1):527. PubMed ID: 34090358
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy.
    Wen X, Otoo MN, Tang J, Brothers T, Ward KE, Asal N, Meador KJ.
    JAMA Neurol; 2024 Aug 01; 81(8):866-874. PubMed ID: 38884986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.